Avapritinib has been approved by the FDA for advanced systemic mastocytosis

Share This Post

August 2021: The FDA approved avapritinib (AyvakitTM, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), which includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL).

EXPLORER (NCT02561988) and PATHFINDER (NCT03580655), two multi-center, single-arm, open-label clinical trials recruiting patients with AdvSM, were used to assess efficacy. The overall response rate (ORR) was the primary efficacy outcome measure, as determined by a central committee using modified IWG-MRT-ECNM criteria. Duration of response (DOR), time to response, and changes in individual markers of mast cell burden were also used to assess efficacy. Avapritinib was given to 53 patients in daily doses of up to 200 mg.

In both studies, the overall response rate (ORR) was 57 percent (95 percent CI: 42, 70) (n=53), with 28 percent complete remissions and 28 percent partial remissions. The median response time was 2.1 months and the median response length was 38.3 months (95 percent confidence interval: 19, not estimable).

Edema, diarrhoea, nausea, and fatigue/asthenia were the most prevalent adverse effects in patients taking AdvSM (incidence 20%).

Patients with AdvSM with platelet counts of less than 50 X 109/L should not be treated with avapritinib.

For individuals with AdvSM, the suggested avapritinib dose is 200 mg orally once daily.

Reference: https://www.fda.gov/

Check details here.

Take second opinion on advanced systemic mastocytosis treatment

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form